{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Bezlotoxumab: A New Drug for the Toxic Effects of Clostridium Difficile

Activity Steps

Description

Accreditation Statement:
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Purpose of Activity

To provide information about the new drug bezlotoxumab.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Describe Clostridium difficile (C. diff) infection and the challenges of its treatment.
  2. Explain the mechanism of action, dosage and administration, contraindications, and side effects of bezlotoxumab.
Price: $10.00

Credits:

  • ACPE 1.0 CH

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0431-0000-22-013-H04-P

Professions: Pharmacist
Test Code: GN0717BPharm
Published: February
Expires: 9/12/2025
Required Passing Score: 9/12 (75%)
Authors: Mark D. Welliver, DNP, CRNA, ARNP
Categories: Pharmacology
Topics: Infection